Role of modified lipoproteins in diabetic macroangiopathy

Diabetes

Volumn 46, Issue SUPPL. 2, 1997, Pages

  Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ANTIBODY TITER; ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETIC MICROANGIOPATHY; GUINEA PIG; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030931368     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.s112     Document Type: Conference Paper

References (27)

1. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991
2. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 344:793-795, 1994
3. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ: Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 91:2488-2496, 1995
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
5. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86:1372-1376, 1989
6. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyysonen K, Palinski W, Witztum JL: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887, 1992
7. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92:3893-3897, 1995
8. Vlassara H, Brownlee M, Cerami AJ Advanced non-enzymatic tissue glycosylation: significance in late diabetic complications. Diabetes Res Clin Pract 7 (Suppl. 1):S103-S108, 1989
9. Witztum JL, Steinbrecher UP, Fisher M, Kesaniemi A: Nonenzymaac glycosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natt Acad Sci USA 80:2757-2761, 1983
10. Curtiss LK, Witztum JL: A novel method for generating region-specific monoclonal antibodies to modified proteins: application to the identification of human glycosylated low density lipoproteins. J Clin Invest 72:1427-1438, 1983
11. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK: Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 25:1109-1116, 1984
12. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10:325-335, 1990
13. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14:32-40, 1994
14. Parums DV, Brown DL, Mitchinson MJ: Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 114:383-387, 1990
15. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G: Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 44:60-66, 1995
16. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G: LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14:1892-1899, 1994
17. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T: Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154:2605-2609, 1994
18. Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 92:821-825, 1995
19. Hansson GK, Holm J, Holm S, Fotev Z, Hedrich HJ, Fingerle J: T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA 88:10530-10534, 1991
20. Roselaar SE, Schonfeld G, Daugherty A: Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 96:1389-1394, 1997
21. Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 64:5-15, 1991
22. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stem D: Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosder Thromb 14:1521-1528, 1994
23. Yan SD, Schmidt AM, Andersen GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
24. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
25. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A, Witztum JL: Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 15:571-582, 1995
26. Witztum JL, Koschinsky T: Metabolic and immunological consequences of glycation of low density lipoproteins. In The Maillard Reaction in Aging, Diabetes, and Nutrition. Baynes JW, Monnier VM, Eds. New York, Alan R. Liss, 1989, p. 219-234
27. Al-Abed Y, Liebich H, Voelter W, Bucala R: Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein. J Biol Chem 271:2892-2896, 1996